Last Updated: November 8, 2026

FOSCAVIR Drug Patent Profile

Name: FOSCAVIR Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

Which patents cover Foscavir, and when can generic versions of Foscavir launch?

Foscavir is a drug marketed by Clinigen Hlthcare and is included in one NDA.

The generic ingredient in FOSCAVIR is foscarnet sodium. There is one drug master file entry for this compound. Ten suppliers are listed for this compound. Additional details are available on the foscarnet sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Foscavir

A generic version of FOSCAVIR was approved as foscarnet sodium by FRESENIUS KABI USA on January 29^th, 2021.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for FOSCAVIR?
What are the global sales for FOSCAVIR?
What is Average Wholesale Price for FOSCAVIR?

Summary for FOSCAVIR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	57
Clinical Trials:	9
Patent Applications:	2,599
Drug Prices:	Drug price information for FOSCAVIR
What excipients (inactive ingredients) are in FOSCAVIR?	FOSCAVIR excipients list
DailyMed Link:	FOSCAVIR at DailyMed

Drug patent expirations by year for FOSCAVIR

Recent Clinical Trials for FOSCAVIR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital, Lille	Phase 2
Biotest	Phase 2
National Cancer Institute (NCI)

See all FOSCAVIR clinical trials

Pharmacology for FOSCAVIR

Drug Class	Pyrophosphate Analog DNA Polymerase Inhibitor
Mechanism of Action	Chelating Activity DNA Polymerase Inhibitors

US Patents and Regulatory Information for FOSCAVIR

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Clinigen Hlthcare	FOSCAVIR	foscarnet sodium	SOLUTION;INTRAVENOUS	020068-001	Sep 27, 1991	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Clinigen Hlthcare	FOSCAVIR	foscarnet sodium	SOLUTION;INTRAVENOUS	020068-002	Sep 27, 1991		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for FOSCAVIR

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Clinigen Hlthcare	FOSCAVIR	foscarnet sodium	SOLUTION;INTRAVENOUS	020068-001	Sep 27, 1991	4,771,041	⤷ Start Trial
Clinigen Hlthcare	FOSCAVIR	foscarnet sodium	SOLUTION;INTRAVENOUS	020068-001	Sep 27, 1991	4,215,113	⤷ Start Trial
Clinigen Hlthcare	FOSCAVIR	foscarnet sodium	SOLUTION;INTRAVENOUS	020068-001	Sep 27, 1991	4,665,062	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for FOSCAVIR

See the table below for patents covering FOSCAVIR around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Austria	369014		⤷ Start Trial
Austria	A465477		⤷ Start Trial
Australia	2650577		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

DrugChatter Q&A for FOSCAVIR

Foscavir cost?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.